Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Transgender Persons Clinical Trial

Official title: Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Status Recruiting

Clinical Trial Summary

The study will test:

1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function

2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function

3. whether estrogen therapy leads to enhanced immune response in older transwormen

Clinical Trial Description

All subjects will participate in a 2-hour oral glucose tolerance test (OGTT) and DXA scan for estimation of lean body mass. Only the transgender subjects will have a repeat OGTT two weeks after discontinuation of Gender Affirming Hormone Therapy (GAHT).

Beta cell function will be correlated with the Estrogen/Testosterone ratio to evaluate the relationship between sex hormones and beta cell function. Plasma Glucagon-like peptide 1 (GLP-1) response during the OGTT will be measured to evaluate if estrogen treatment modulates insulin secretion by increasing GLP-1 secretion. ;

Related Conditions & MeSH terms

• Transgender Persons

• NCT number: NCT04515472
• Study type: Interventional
• Source: The University of Texas Health Science Center at San Antonio
• Contact: Devjit Tripathy, MD
• Phone: 210-617-5300
• Email: tripathy@uthscsa.edu
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 17, 2020
• Completion date: July 2024